Nexalin Technology, Inc.
NXLNASDAQHealthcareMedical Devices

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.

Company Information

CEOMark White
Founded2010
IPO DateSeptember 16, 2022
Employees6
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone832 260 0222
Address
1776 Yorktown, Suite 550 Houston, Texas 77056 United States

Corporate Identifiers

CIK0001527352
CUSIP65345B201
ISINUS65345B2016
EIN27-5566468
SIC3845

Leadership Team & Key Executives

Mark White
President, Chief Executive Officer and Director
Dr. David Owens M.D.
Chief Medical Officer, Member of Scientific Advisory Board and Director
Carolyn Shelton
Executive Vice President of Clinical, Quality and Regulatory Affairs
John Patrick Claude
Co-Founder and Director of Engineering and Development
Justin Van Fleet CPA
Chief Financial Officer